ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has announced encouraging topline findings from its Phase 4 SYNCHRONICITY trial, which evaluates the use of fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis affecting the posterior segment of the eye.
Trial Overview and Key Results
The trial successfully met both co-primary endpoints, showing a statistically significant mean change from baseline in best corrected visual acuity (BCVA) and central subfield thickness (CST) after six months for the 108 participants.
We are encouraged by the positive results from the SYNCHRONICITY trial, which continue to support the use of fluocinolone acetonide intravitreal implant in patients with chronic NIU-PS being treated by retina specialists.
Nikhil Lalwani, President and CEO of ANI Pharmaceuticals
- Mean baseline BCVA improved by +3.6 letters in participants.
- 29% of patients experienced treatment-related adverse events.
Common adverse events included ocular hypertension and cataracts, aligning with findings from previous studies on fluocinolone acetonide. Notably, 18% of patients experienced an increase in intraocular pressure.
Implications for Future Treatments
The SYNCHRONICITY trial adds to the growing body of evidence supporting fluocinolone acetonide as a viable option for managing chronic NIU-PS. The findings will be further discussed at upcoming medical conferences in late 2026, potentially influencing treatment protocols.
Chronic non-infectious uveitis is a significant cause of vision loss, and effective management is crucial. This study emphasizes the need for ongoing research in the field of ophthalmology.